Kezar Life Sciences
300 Utah Ave
South San Francisco
5 articles with Kezar Life Sciences
Autolus Therapeutics snagged $150 million from its initial public offering, about $25 million more than the company initially expected when it began its roadshow effort earlier this month.
It’s a super-busy week for biotech initial public offerings (IPOs) with six companies raking in a total of around $568 million.
Initial public offering of 5,000,000 shares of its common stock at a public offering price of $15.00 per share
5/29/2018It’s been a busy month for IPOs. Numerous biotech companies announced their intentions to publicly list their stock on an exchange in the U.S. or abroad in order to gain new funding to advance developmental programs.
Kezar Life Sciences Strengthens Management Team with the Appointments of Niti Goel, MD, as Chief Medical Officer and Marc Belsky as Chief Financial Officer
Kezar Life Sciences announced the appointments of Niti Goel, MD, as Chief Medical Officer and Marc Belsky as Chief Financial Officer.